MeSH D012778 - short bowel syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Emmaus Life Sciences | Glutamine | Endari | 2017-07-07 | |||
| Glutamine | Nutrestore | 2004-06-10 | ||||
| Takeda | Teduglutide | Revestive | 2012-08-30 | |||
| Teduglutide | Gattex | 2022-09-18 | 2012-12-21 |
Clinical Trials
Historical Success Rate
Phase 1
17%1/6
Phase 2
29%2/7
Phase 3
33%1/3
Approved: 0Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use